Trial Profile
A Clinical Study to Evaluate the Efficacy and Safety of MK0633 in Patients With Atherosclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Setileuton (Primary)
- Indications Atherosclerosis
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 27 Dec 2007 The expected completion date for this trial is now 1 Apr 2008.
- 29 Jan 2007 New trial record.